Actividad y tratamiento de la artritis reumatoide

Cynthia Yesenia Urbina Aucancela, Geyla Yomar Carrera Montero, Omar Santiago Quintana Domínguez, Lucia Nataly Guama Bonilla

Texto completo:

PDF XML

Resumen

Introducción: el diagnóstico y el tratamiento de la artritis reumatoide temprano en el curso de la enfermedad proporciona alivio de los síntomas y también previene el daño estructural a largo plazo y el deterioro funcional, con una mejora concomitante en la calidad de vida.
Objetivo: exponer enfoques de la artritis reumatoide en cuanto al tratamiento y comportamiento de la actividad de dicha enfermedad.
Desarrollo: el reconocimiento de los pacientes con enfermedad que progresa rápidamente es fundamental para identificar candidatos en los cuales la terapia intensiva puede tener el mayor impacto, en términos de prevenir la progresión de la enfermedad.
Conclusiones: los datos acumulados muestran que las estrategias de tratamiento intensivo con agentes biológicos, especialmente los inhibidores del TNF, son más efectivas que la monoterapia secuencial o la terapia de combinación progresiva. Estos muestran una eficacia sustancial en combinación con MTX, proporcionando beneficios y mejoras rápidos y sustanciales en los resultados del paciente.

Palabras clave

artritis reumatoide; curso de la enfermedad, tratamiento, comportamiento de la actividad

Referencias

Emery P, Seto Y: Role of biologics in early arthritis. Exp Rheumatol 2003, 21(Suppl 30):S191-S194.

American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines: Guidelines for the management of rheumatoid arthritis. 2002 update. Arthritis Rheum 2002, 46:328-346.

Chen S, Gill MA, Luu CH, Takami S: Pain and rheumatoid arthritis: an update. Drug Topics 2000, April 3:47-56.

Klarenbeek, NB, Güler-Yüksel M, van der Kooij SM, van der Heijde DMFM, Huizinga TWJ, Kerstens PJMS, Peeters AJ, Ronday HK, Westedt ML, Dijkmans BAC, Allaart CF: Clinical outcomes of four diff erent treatment strategies in patients with recent-onset rheumatoid arthritis: 5-year results of the BeSt Study. Ann Rheum Dis 2008, 67(Suppl II):187.

Arvidsson NG, Gubjornsson B, Hallgren R, Larrson A: Concordant message of diff erent infl ammatory markers in patients with rheumatoid arthritis. Ups J Med Sci 1998, 103:35-42.

Skogh T, Gustafsson D, Kjellberg M, Husberg M: Twenty eight joint count disease activity score in recent onset rheumatoid arthritis using C reactive protein instead of erythrocyte sedimentation rate. Ann Rheum Dis 2003, 62:681-682.

Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, Bombardier S, Choi H, Dougados M, Emery P, Gomez-Reino J, Keystone E, Koch G, Kvien TK, Martin-Mola E, Matucci-Cerinic M, Michaud K, O’Dell J, Paulus H, Pincus T, Richards P, Simon L, Siegel J, Smolen, JS, Sokka T, Strand GV, Tugwell P, van der Heijde D, van Riel P, et al.: Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis 2008, 67:1360-1364.

Salaffi F, Cimmino MA, Leardini G, Gasparini S, Grassi W; Epidemiology Study Group of the Italian Society of Rheumatology: Disease activity assessment of rheumatoid arthritis in daily practice: validity, internal consistency, reliability, and congruency of the disease activity score including 28 joints compared with the clinical disease activity index. Clin Exp Rheumatol 2009, 27:552-559.

Balsa A, de Miguel E, Castillo C, Peiteado D, Martín-Mola E: Superiority of SDAI over DAS-28 in assessment of remission in rheumatoid arthritis patients using power Doppler ultrasonography as a gold standard. Rheumatology 2010, 49:683-690.

Garnero P, Geusens P, Landewé R: Biochemical markers of joint tissue turnover in early rheumatoid arthritis. Clin Exp Rheumatol 2003, 21(5 Suppl 31):S54-S58.

Emery P: The Dunlop–Dottridge Lecture: prognosis in inflammatory arthritis: the value of HLA genotyping and the oncological analogy. J Rheumatol 1997, 24:1436-1442.

Emery P, McInnes IB, van Vollenhoven R, Kraan MC: Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis. Rheumatology (Oxford) 2008, 47:392-398.

Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM: How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002, 46:357-365.

Mitka M: Early rheumatoid arthritis treatments weighed. JAMA 2005, 294:3073-3074.

McInnes IB: Attitudes of rheumatologists to rapidly progressing rheumatoid arthritis [abstract]. Rheumatology 2007, 6(Suppl 1):i89.

Sesin CA, Bingham CO 3rd: Remission in rheumatoid arthritis: wishful thinking or clinical reality? Semin Arthritis Rheum 2005, 35:185-196.

Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aleteha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomex-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Schholte M, Scott DL, Sokka T, Valesini G, van Vollenhoven R, et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975.

Chen S, Gill MA, Luu CH, Takami S: Pain and rheumatoid arthritis: an update. Drug Topics 2000, April 3:47-56.

Keystone EC: The role of tumor necrosis factor antagonism in clinical practice. J Rheumatol 1999, 26(Suppl 57):22-28.

Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Kincaid W, Porter D: Eff ect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004, 364:263-269.

Odeh M: New insights into the pathogenesis and treatment of rheumatoid arthritis. Clin Immunol Immunopathol 1997, 83:103-116.

Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL Jr, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW,O’Dell J, Turkiewicz AM, Furst DE; American College of Rheumatology: American College of Rheumatology 2008 recommendations for the use of non-biologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008, 59:762-784.

American College of Rheumatology, Ad Hoc Committee on Clinical Guidelines: Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996, 39:713-722.

Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, Singh A, Pedersen RD, Koenig AS, Freundlich B: Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008, 372:375-382.

Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT: The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006, 54:26-37.

Quinn MA, Conaghan PG, O’Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P: Very early treatment with infl iximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefi t after infl iximab withdrawal. Results from a twelvemonth randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005, 52:27-35.

Breedveld FC, Combe B: Understanding emerging treatment paradigms in rheumatoid arthritis. Arthritis Research & Therapy 2011, 13(Suppl 1):S3.

Enlaces refback

  • No hay ningún enlace refback.


Copyright (c) 2020 Cynthia Yesenia Urbina Aucancela

Licencia de Creative Commons
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.